The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon

Journal of the American College of Cardiology

Volumn 44, Issue 1, 2004, Pages 57-62

  Beltrame, John F ^a   Turner, Stuart P ^a   Leslie, Sue L ^a   Solomon, Patty ^a   Freedman, Saul B ^b   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

coronary slow flow phenomenon; corrected TIMI frame count; CSFP; CTFC; ECG; electrocardiogram; Health Outcome Study Short Form 36; LAD; left anterior descending artery; SF 36; Thrombolysis In Myocardial Infarction; TIMI

Indexed keywords

MIBEFRADIL; NITRATE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MALE; MEDICAL ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REDUCTION;

ADULT; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; CROSS-OVER STUDIES; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIBEFRADIL; MIDDLE AGED; PATIENT COMPLIANCE; STATISTICS; SYSTOLE; TREATMENT OUTCOME; TROPONIN I;

EID: 3242779319     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.055     Document Type: Article

References (13)

1. Mangieri E., Macchiarelli G., Ciavolella M., et al. Slow coronary flow Clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 37:1996;375-381
2. Mosseri M., Yarom R., Gotsman M.S., Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina and patent large coronary arteries. Circulation. 74:1986;964-972
3. Beltrame J.F., Limaye S.B., Wuttke R., Horowitz J.D. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 146:2003;84-90
4. Beltrame J.F., Limaye S.B., Horowitz J.D. The coronary slow flow phenomenon - a new coronary microvascular disorder. Cardiology. 97:2002;197-202
5. Diver D.J., Bier J.D., Ferreira P.E., et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial). Am J Cardiol. 74:1994;531-537
6. Chesebro J.H., Knatterud G.L., Roberts R., et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. clinical findings through hospital discharge. Circulation. 76:1987;142-154
7. Prueksaritanont T., Ma B., Tang C., et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors An in vitro investigation with human liver preparations. Br J Clin Pharmacol. 47:1999;291-298
8. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count A quantitative method of assessing coronary artery flow. Circulation. 93:1996;879-888
9. Ware J.E. Jr., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 30:1992;473-483
10. Jones B., Kenward M.G. Design and Analysis of Cross-Over Trials. 1989;Chapman and Hall, London
11. Kurtoglu N., Akcay A., Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol. 87:2001;777-779
12. Gustafsson F., Andreasen D., Salomonsson M., Jensen B.L., Holstein-Rathlou N.H. Conducted vasoconstriction in rat mesenteric arterioles Role for dihydropyridine-insensitive ca(2+) channels. Am J Physiol Heart Circ Physiol. 280:2001;H582-H590
13. Becquemont L., Funck-Brentano C., Jaillon P. Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Fundam Clin Pharmacol. 13:1999;232-236